Microvesicles released from glioblastoma cells carry information that may guide treatment
A team of researchers led by investigators at the Albert Einstein College of Medicine of Yeshiva University has determined that certain commonly-prescribed medications may have the unintended consequence of increasing the frequency of migraine attacks. This important finding could alter the way doctors prescribe migraine medicines. In a recent article published in the journal Headache
Full Post: Medications containing barbiturates or narcotics may make migraine worse
Microvesicles - tiny membrane-covered sacs - released from glioblastoma cells contain molecules that may provide data that can guide treatment of the deadly brain tumor.
In their report in the December 2008 Nature Cell Biology, which is receiving early online release, Massachusetts General Hospital (MGH) researchers describe finding tumor-associated RNA and proteins in membrane microvesicles called exosomes in blood samples from glioblastoma patients. Detailed analysis of exosome contents identified factors that could facilitate a tumor’s growth through delivery of genetic information or proteins, or signify its vulnerability to particular medications.
“Glioblastomas release exosomes in sufficient quantities to pass the blood-brain barrier. We were able to isolate them, analyze the RNA transcripts and show how they might be used as biomarkers to guide targeted therapy and monitor treatment response,” says Johan Skog, PhD, the study’s lead author, who works in the laboratory of Xandra Breakefield, PhD, at the MGH Neuroscience Center. “Exosomes also may someday be used to deliver therapeutic molecules to the site of a tumor,” he added.
Many types of cells release exosomes as part of normal cell-to-cell communication, and several types of tumors are known to shed exosomes containing proteins that can alter the cellular environment to favor tumor growth. The current investigation is believed to be the first to carefully analyze the contents of exosomes shed from glioblastoma cells and characterize their contents.
The investigators first analyzed tumor cells from three glioblastomas and verified that the cells released exosomes containing RNA and protein molecules. Some messenger RNAs related to activities such as cell proliferation and migration, angiogenesis, and immune response were highly abundant in the exosomes. When glioblastoma exosomes were cultured with normal cells, tumor RNA was delivered into the normal cells and generated its encoded protein, supporting the role of exosome-delivered RNA in manipulating the cellular environment.
To study the potential of glioblastoma exosomes as markers of a tumor’s genetic makeup, the researchers analyzed tumor tissue and blood serum from 25 glioblastoma patients and were able both to find tumor exosomes and to identify, in some tissue samples, a mutation in the epidermal growth factor receptor (EGFR) gene that characterizes a tumor subtype. In two patients, an EGFR mutation that did not appear in the tumor tissue sample was identified by exosome analysis, reflecting how a surgical biopsy can miss tissue conveying critical information because of the often-chaotic diversity of cells within a tumor.
“It is known that the effects of some anticancer drugs depend on a tumor’s genetic mutational profile, so our results have broad implications for personalized medicine,” explains Skog, who is an instructor in Neurology at Harvard Medical School. “Detecting mutational profiles through a noninvasive blood test could allow us to monitor how a tumor’s genetic makeup changes in response to therapy, which may necessitate changes in treatment strategy.” Skog, Breakefield and their colleagues are also investigating the role of exosomes in other solid tumors and how they may help monitor additional tumor-associated mutations.
The current study was supported by grants from the Wenner-Gren Foundation, Stiftelsen Olle Engkvist Byggmastare, the National Cancer Institute, the Brain Tumor Society and the American Brain Tumor Association. The MGH’s provisional patent on the work described in this study has been exclusively licensed to Exosome Diagnostics, Inc. Subsequent to the completion of this work, Skog was appointed the company’s director of Research, while maintaining his position at MGH.
Tiny vesicles called exosomes released into the bloodstream from aggressive brain tumors contain genetic signatures that may help guide future diagnosis and treatment of this deadly disease. In their report in the December issue of Nature Cell Biology (DOI: 10.1038/ncb1800), Massachusetts General Hospital researchers describe finding tumor-associated gene messages in the blood samples of
Full Post: Blood exosomes shown to contain tumor-specific genetic information for brain cancer
Researchers at Georgetown University Medical Center have found a gene they say is inactivated in two aggressive cancers - malignant melanoma, a form of skin cancer, and glioblastoma multiforme, a lethal brain tumor. They add that because this gene, known as PTPRD, has recently been found to be inactivated in several other cancers as well,
Full Post: GUMC researchers find gene inactivated in two aggressive cancers
UC Davis Cancer Center researchers report today the discovery of a molecule that targets glioblastoma, a highly deadly form of cancer. The finding, which is published in the January 2009 issue of the European Journal of Nuclear Medicine and Molecular Imaging , provides hope for effectively treating an incurable cancer. Glioblastoma is the most common
Full Post: Discovery of molecule that targets brain tumors
Working with a nanoparticle designed to target and image glioblastoma, a form of brain cancer, investigators at the University of Washington in Seattle have found that these same nanoparticles inhibit tumor cell invasion, one of the key events that leads to the metastatic spread of cancer. The investigators have also determined how the nanoparticles exert
Full Post: Toxin-nanoparticle combo inhibits brain cancer invasion while imaging tumors
Researchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastoma-the most common and deadly brain cancer in humans-that closely resembles the development and progression of human brain tumors that arise naturally. “Mouse models of human cancer have taught us a great deal about the basic principles of cancer biology,”
Full Post: A novel glioblastoma mouse model developed